Arcellx, Inc.
ACLX
株式のランク
#2787
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
株価
$115.07
最終同期: 2026-05-15
時価総額
$6.73B
変化（1日）
0.00%
変化（1年）
32.61%
国
US
取引 Arcellx, Inc. (ACLX)
カテゴリー
Healthcare
Arcellx, Inc.（ACLX）のP/S比率
October 2026 時点のP/S比率 TTM: 475.55
Arcellx, Inc. の最新の財務報告および株価によると、現在のP/S比率（TTM）は 475.55 です。2023 年末時点でのP/S比率は 24.18 でした。
Arcellx, Inc. の P/S 比率の履歴（2018 ～ 2026）
各年末時点のP/S比率
| 年 | P/S比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 475.55 | 1,149.47% |
| 2024 | 38.06 | 57.41% |
| 2023 | 24.18 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
同業他社のP/S比率
| 企業 | P/S比率 | P/S比率の差 | 国 |
|---|---|---|---|
| 10.02 | -97.89% |
US
|
|
| 40.55 | -91.47% |
US
|
|
| 3.96 | -99.17% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -97.87% |
NL
|
